Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for ROS1-positive non-small-cell lung cancer, drawn from the whole corpus: 10 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No randomised trial compares the ROS1 inhibitors; choice rests on single-arm response rates and side-effect profiles.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dizziness, weight gain and paraesthesia from TRK inhibition limit the current brain-penetrant drugs.
Resistance through MET, KRAS and other bypass routes has no approved targeted option.
Nothing recorded yet.
Nothing recorded yet.
Background: On-target resistance mutations (gatekeeper, solvent-front, compound). Also on OnCo: Resistance atlas · Lines of therapy.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 7 changes by month →When this page itself was last checked or edited.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.